Pharma companies exposed to transfer pricing challenges
The interaction of Poland’s transfer pricing rules and reimbursement law means the pharmaceutical industry is faced with complex compliance demands, explains Aneta Blazejewska-Gaczynska and Slawomir Buszko of Ernst & Young.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
